ReviewJournal of clinical hypertension (Greenwich, Conn.)2013
Assessing blood pressure responses to noncardiovascular drugs: the beneficial role of ambulatory blood pressure monitoring.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 22 citations in OpenAlex.
- A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial.Blood pressure monitoring · 2018Trial
- Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.Journal of hypertension · 2017Trial
- Recommended standards for assessing blood pressure in human research where blood pressure or hypertension is a major focus.Journal of human hypertension · 2017Article
- Recommended Standards for Assessing Blood Pressure in Human Research Where Blood Pressure or Hypertension Is a Major Focus.Kidney international reports · 2017Article
- Recommended standards for assessing blood pressure in human research where blood pressure or hypertension is a major focus.Journal of clinical hypertension (Greenwich, Conn.) · 2017Article
- Raising the Bar in Renal Sympathetic Denervation Research and Reporting.Journal of clinical hypertension (Greenwich, Conn.) · 2016Article
- Diagnosis and treatment of resistant hypertension: the critical role of ambulatory blood pressure monitoring.Journal of clinical hypertension (Greenwich, Conn.) · 2013Article
- A comparison of two ambulatory blood pressure monitors worn at the same time.Journal of clinical hypertension (Greenwich, Conn.) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has become apparent that noncardiovascular drugs can affect blood pressure (BP) in an off-target manner, either by raising or lowering pressure or by negating the beneficial hypotensive effect of concomitantly prescribed antihypertensives. This paper presents compelling evidence that ambulatory blood pressure monitoring (ABPM) should be used to detect BP effects during the development of noncardiovascular drugs. The requirements for standardizing ABPM to obtain the most information from the least number of participants and the many advantages of obtaining a 24-hour BP profile are discussed. The use of ABPM in trials of antihypertensive agents, though differing in purpose (the demonstration of BP-lowering efficacy) from the use of ABPM in trials of noncardiovascular drugs (the demonstration of any off-target effect on BP) nonetheless provides methodological similarities that can be applied in both contexts with advantage. The paper also considers whether there are lessons to be learned from a regulatory science approach that is designed to prospectively identify unacceptable off-target cardiac effects of noncardiac drugs and offers some thoughts on how a future paradigm of standardized use of ABPM to assess off-target BP effects during the development of noncardiovascular drugs might benefit patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.